Ben Ayers, DPhil

Vice President, Antibody-Drug Conjugates at Hummingbird Bioscience, Singapore

Speaker

Ben is the Vice President of Antibody-Drug Conjugates at Hummingbird Bioscience. With close to two decades of experience in the biopharma sector, Ben leads the strategy and development of the Antibody-Drug Conjugates platform and programs at Hummingbird Bioscience. Ben also held strategy and preclinical roles since joining Hummingbird Bioscience in 2020.

Prior to joining Hummingbird Bioscience, Ben advised companies on commercial strategy in APAC at ZS Associates, a healthcare-focused management consulting firm. Ben has accumulated a decade of experience in medicinal chemistry research in a wide range of therapeutic areas including oncology, tropical disease, diabetes, cystic fibrosis, and lysosomal storage diseases at Novartis, the Institute of Cancer Research, and the University of Oxford.

Ben holds a M.Chem. in Chemistry and a D.Phil in Organic Chemistry from the University of Oxford.